BioHealth Business Daily (CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM)

Administrator — Wed, 07 Apr 2010 18:25:31 +0000

There are more recognized stocks in today’s edition of the BioHealth Business Daily. We are seeing significant and unusual moves, or implications, in shares of Celgene Corporation (NASDAQ: CELG), DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA), Encorium Group, Inc. (NASDAQ: ENCO), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), OSI Pharmaceuticals Inc. (NASDAQ: OSIP), Pfizer, Inc. (NYSE: PFE), PURE Bioscience (NASDAQ: PURE), Rexahn Pharmaceuticals, Inc. (AMEX: RNN), and Sequenom Inc. (NASDAQ: SQNM).

We have outlined the news and the impact, volume and relative moves, and added in color on each where appropriate.

Celgene Corporation (NASDAQ: CELG) is up ahead of tomorrow’s R&D day for the first time. We outlined this in full at InvestorPlace, but the other thing to consider is a potential stock split. Shares are up almost 1% at $63.92.

DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA) is a mystery move other than a large block trade, which may be enough to whip it around since average volume is barely 60,000 shares. Shares are now up 17.7% at $2.06 on 475,000 shares. This marks a 52-week high as well and the new 52-week range is $0.88 to $2.06.

Encorium Group, Inc. (NASDAQ: ENCO) continues to be a puzzle…. Shares are up 13% at $3.48 on 1.8 million shares. This is the new micro-cap stock for day traders looking for those ten-baggers. The market cap is a mere $11.43 million.

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) is up after an analyst praised it in a “Wall Street Transcript” interview. Shares are up 4.7% at $3.33 on 2.6 million shares (almost 150% normal volume) and the 52-week range is $0.14 to $3.56.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is higher after Needham & Co. began coverage today with a BUY rating. Shares are up 2.7% at $5.25 on 300,000 shares (over 150% normal volume).

OSI Pharmaceuticals Inc. (NASDAQ: OSIP) may seem boring and not worthy of coverage today on the surface. However, Joe Kunkle of OptionsHawk.com pointed out an unusual trade in options confirming some of our concerns that the Astellas $52 offer may not ever get above the $60 price seen in the quest for a higher buyout.

Filed under: Biotech, Drug companies, Medical, Trading Alert Tagged: CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM

The 52-Week Low Club

247wallst — Mon, 10 Sep 2007 15:44:34 +0000

Krispy Kreme (KKD) Downgrades, bad numbers. You name it. Drops to $3.24 from 52-week high of $13.94.

BearingPoint (BE) Consulting firm releases numbers late, and they are bad. Drops to $4.80 from 52-week high of $9.

Office Depot (ODP) Still spinning down from bad results. Down to $17.79 from 52-week high of $44.69.

Hovnanian Enterprises (HOV) Another home builder makes another 52-week low at $9.93 down from $38.66.

Legg Mason (LM) Mutual fund company continues its fall. Moves down to $76.80 from $110.17.

DUSA Pharmaceuticals (DUSA) Quaterly results failed to impress. Off to $1.63 from 52-week high of $5.89.

Cognizant Technology (CTSH) No news. Just a bad day. Drops to $67.60 from 52-week high of $95.55.

Douglas A. McIntyre

24/7 Wall St. » DUSA

BioHealth Business Daily (CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM)

The 52-Week Low Club